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OBJECTIVES: To determine patterns of and trends in
contributions to central nervous system (CNS) polyphar-
macy, defined by the Beers Criteria as three or more CNS-
active medications of each medication class, of adults aged
65 and older seen in U.S. outpatient medical practices.
DESIGN: National Ambulatory Medical Care Survey
(2004–2013).
SETTING: U.S. outpatient medical care.
PARTICIPANTS: Visits by older adults to outpatient
physicians (N = 97,910).
MEASUREMENTS: Visits including three or more CNS
medications including antipsychotics, benzodiazepines,
nonbenzodiazepine benzodiazepine receptor agonist hyp-
notics (NBRAs), tricyclic antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs), and opioids. The
proportion of CNS polypharmacy that each medication
class contributed during 2011 to 2013 was determined,
and then logistic regression was used to determine trends
from 2004 to 2013 in the contribution of individual medi-
cation classes to such polypharmacy.
RESULTS: Of recent CNS polypharmacy visits, 76.2%
included an opioid, and 61.8% included a benzodiazepine;
66.0% of the polypharmacy visits with benzodiazepines
included opioids, and 53.3% of the polypharmacy visits
with opioids included benzodiazepines. Between 2011 and
2013, opioid and benzodiazepine co-prescribing occurred
at approximately 1.50 million visits (95% confidence inter-
val (CI) = 1.23–1.78 million) annually. From 2004 (refer-
ence) to 2013, the proportion of polypharmacy visits with
opioids rose from 69.6% to 76.2% (adjusted odds
ratio = 2.15, 95% CI = 1.19–3.91, P = .01), and the cor-
responding proportion that included benzodiazepines fell.
Of the polypharmacy visits, the odds of SSRI, NBRA, and
antipsychotic use were unchanged, and that of TCAs
decreased.
CONCLUSION: In older adults, opioid use appears to be
largely driving the recent national increase in CNS
polypharmacy. Although concomitant use of opioids and
benzodiazepines is associated with greater mortality, they
are the most common contributors to CNS polypharmacy
in older adults. J Am Geriatr Soc 65:2052–2056, 2017.
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When the Beers Criteria for potentially inappropriatemedication use in elderly adults were first intro-
duced 20 years ago, a select number of psychotropic medi-
cations were included, primarily because of their sedating
effects: long-acting benzodiazepines, short-acting benzodi-
azepines above a low dosage, amitriptyline, and doxepin.1
With each subsequent revision of the criteria, the list of
psychotropic medications has grown, along with the evi-
dence of associated risks2–5; the 2015 version now includes
virtually every class of psychotropic medication.6 The
potential harms for older adults are particularly troubling
given growing evidence that a significant proportion of
psychotropic prescribing in older adults occurs in the
absence of significant psychiatric symptoms7 or a clearly
defined mental health disorder.8,9
As the number of psychotropic medications in the
Beers Criteria increased, opioids were not featured promi-
nently, but their use is now included as potentially inap-
propriate in a measure of central nervous system (CNS)
polypharmacy, defined as three or more prescriptions from
the following classes: antipsychotics, benzodiazepines, non-
benzodiazepine benzodiazepine receptor agonist hypnotics
(NBRAs), tricyclic antidepressants (TCAs), selective sero-
tonin reuptake inhibitors (SSRIs), and opioids.6 This revi-
sion follows evidence that CNS polypharmacy (opioids
included) is associated with risk of falls5 and cognitive
decline.10 In light of the opioid epidemic, there is now
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even greater attention focused on combined use of CNS
medications. Co-prescribing of opioids and benzodi-
azepines is a particular cause for concern given their com-
mon role together in pharmaceutical overdose deaths. The
risk of mortality increases with the dose of benzodiazepine
prescribed.11 The U.S. Food and Drug Administration
(FDA) recently issued a black box warning advising of slo-
wed breathing and death caused by co-prescribing opioids
with CNS depressants, including benzodiazepines, NBRAs,
and antipsychotics,12 all of which are included in the Beers
polypharmacy measure.
The use of individual psychotropic medication classes
and prescription opioids has increased in older adults in
the United States,13,14 with CNS polypharmacy visits for
older adults more than doubling between 2004–06 and
2011–13.15 Although polypharmacy has risen overall, it is
unclear which specific medication classes account for this
growth. To address CNS polypharmacy, it is important to
understand which medications and medication combina-
tions are most common. The present study used data
from the National Ambulatory Medical Care Survey
(NAMCS), a nationally representative survey of visits to
office-based physicians in the United States, to better
characterize the relative contribution of specific medica-
tion classes to CNS polypharmacy and how this has chan-
ged over time.
METHODS
Sample
The analysis used data from NAMCS from 2004 through
2013, the most recent year available. NAMCS is a
national probability sample survey of office-based and
community health center–based physicians conducted
annually and designed to “provide objective, reliable infor-
mation about the provision and use of ambulatory medical
care services in the United States”.16 Non-federally
employed physicians engaged in office-based practice are
sampled from the American Medical Association and
American Osteopathic Association master files; physicians
in anesthesiology, pathology, and radiology are excluded.
Throughout the year, each participating physician is
assigned a 1-week reporting period, with data collected
from a random sample of visits during that week. For
very small practices, every visit may be included; for
large practices, 10% of visits may be included.17 Encoun-
ters such as house calls or in institutional settings (e.g.,
nursing homes) are not included. For survey years before
2012, physicians, their office staff, or field representatives
of the U.S. Census Bureau recorded data for selected vis-
its on a standardized form. Beginning in 2012, NAMCS
implemented computer-assisted data collection, which
Census staff primarily performed. The 2013 NAMCS
public use data file does not include visits to community
health centers, so such visits from other years were
excluded from analysis, as NAMCS recommends. Addi-
tional technical information concerning the survey sam-
pling design and nonresponse adjustment is provided
elsewhere.17 The current analysis was drawn from visits
of individuals aged 65 and older to all outpatient provi-
ders (N = 97,910).
Medications and Other Visit Characteristics
Survey data included up to eight medications prescribed,
ordered, supplied, administered, or continued during each
visit. Although the 2012 and 2013 surveys included up to
10 medications, this analysis used only the first eight listed
medications to be consistent across all years. The 2015
American Geriatrics Society Beers Criteria includes use of
three or more CNS medication classes as potentially inap-
propriate: antipsychotics, benzodiazepines, NBRAs, TCAs,
SSRIs, and opioids. Medications in NAMCS are assigned
to therapeutic classes according to Lexicon Plus, a propri-
etary database of Cerner Multum, Inc.17 A visit was classi-
fied as meeting the Beers CNS polypharmacy criteria if it
included three or more medications from any of these
classes.
For this analysis, basic demographic data collected,
such as patient age, sex, and race and ethnicity were also
included. NAMCS classifies physicians into 15 specialty
groups; this analysis includes visits to all physicians, cate-
gorized as family medicine, internal medicine, psychiatry,
or other medical specialties.
Statistical Methods
Survey years (2004–06, 2007–10, 2011–13) were
grouped as NAMCS recommends to produce more-reli-
able annual visit rate estimates.18 All analyses were com-
pleted using survey design elements for visit weight,
clustering within physician practice, and stratification to
allow national inferences.17 First, all older adult visits
across the study period were compared according to
basic demographic and visit characteristics using differ-
ence in proportion tests. Next, the relative contribution
of each medication class to CNS polypharmacy overall
was determined for the most-recent time period (2011–
13). Finally, the contribution of these medication classes
to CNS polypharmacy during each time period was
determined, and logistic regression was used to deter-
mine how odds of use for each class changed over time.
For example, an odds ratio of 2.0 means that a visit in
2013 had twice the odds of that medication class con-
tributing to CNS polypharmacy visits of a visit in 2004.
Regression models were adjusted for age, sex, and race
and ethnicity. Because the Beers polypharmacy measure
does not include diagnosis-based exclusions, the analyses
were not adjusted for clinical diagnosis. Analyses were
conducted in Stata version 13.1 (Stata Corp., College
Station, TX) using two-sided tests with a = .05.
RESULTS
Background characteristics of NAMCS visits by adults
aged 65 and older are presented in Table 1. During the
study period, there were 97,910 office visits, 1,062 of
which met criteria for CNS polypharmacy. As reported
previously, between 2011 and 2013, there was polyphar-
macy at 1.3% of all outpatient encounters of older
adults.15 Opioids were the most commonly prescribed
medication group of CNS polypharmacy encounters
(76.2%), followed by benzodiazepines (61.8%) and SSRIs
(51.5%) (Table 2). Although opioids and benzodiazepines
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were the most-common medications in polypharmacy vis-
its, they were also most commonly used with each other.
Of individuals with CNS polypharmacy that included an
opioid, 53.3% were co-prescribed a benzodiazepine; of
individuals with CNS polypharmacy that included a ben-
zodiazepine, 66.0% were co-prescribed an opioid. Between
2011 and 2013, this opioid and benzodiazepine co-pre-
scribing occurred at approximately 1.50 million visits
(95% confidence interval (CI) = 1.23–1.78 million) annu-
ally. Opioid co-prescribing was the least common of CNS
polypharmacy that included an antipsychotic, just 35.9%
of those prescribed an antipsychotic medication were also
prescribed an opioid. Overall, TCAs were the least com-
mon class, prescribed at just 10.8% of CNS polypharmacy
encounters overall and the least commonly prescribed with
each other medication class.
In CNS polypharmacy encounters, opioids were the
most-common medication class and the only class in
which the odds of that medication class contributing to
CNS polypharmacy visits increased from 2004 to 2013
(adjusted odds ratio (aOR) = 2.15, 95% CI = 1.19–3.91,
P = .01) (Table 3). Although the odds of benzodiazepines
as a polypharmacy component decreased during the
study period, they were still the second-most-commonly
prescribed medication group. The odds of SSRIs,
NBRAs, or antipsychotics as a polypharmacy component
were unchanged over the study period. TCA use
decreased significantly, falling from 23.9% to 10.8%
(aOR = 0.31, 95% CI = 0.15–0.66, P = .002).
DISCUSSION
Opioids are the most-common component of CNS
polypharmacy in older adults in the United States and
account for the greatest share of the overall increase in
CNS polypharmacy. Although the odds of benzodiazepine
use decreased slightly during the study interval, benzodi-
azepines remained the second-most-common polypharmacy
component. Although the Beers CNS polypharmacy mea-
sure cites the risk of falls as its primary rationale, the
recent FDA black box warning primarily concerns risk of
respiratory suppression and death due to concomitant use
of opioids and other CNS depressants, most notably ben-
zodiazepines. More than 30% of overdose deaths of U.S.
veterans related to opioids also include benzodiazepines.19
Therefore, it is particularly troubling that opioids and ben-
zodiazepines are the two medication groups that most con-
tribute to CNS polypharmacy in older adults.
From 2004 to 2013, although polypharmacy grew
overall, the odds of SSRIs, NBRAs, or antipsychotics as a
polypharmacy component were unchanged. This is consis-
tent with previous analyses suggesting growth of these
individual medication classes.15,20–22 Although the opioid-
specific growth may be attributed to the emphasis on treat-
ment of pain, growth of other medication classes may
reflect polypharmacy used to target other specific indica-
tion (e.g., depression) or more-widespread use of medica-
tions for multiple off-label indications. For example,
greater use of quetiapine may reflect indication expansion
Table 1. Characteristics of Visits of Older Adults to Office-Based Physicians in the United States: 2004–2013
Characteristic
2004–06, n = 21,029 2007–10, n = 31,516 2011–13, n = 45,365
Chi-square P-value%a
Demographic
Age
65–74 47.8 49.7 51.2 15.88 <.001
75–84 40.1 37.1 34.7
≥85 12.1 13.2 13.5
Sex
Male 41.5 42.9 43.2 4.06 .02
Female 58.6 57.1 56.8
Race and ethnicity
Non-Hispanic whiteb 85.6 84.2 84.9 0.91 .45
Non-Hispanic black 7.2 7.9 7.2
Hispanic 7.2 7.9 7.9
Diagnosisc
Depression 1.7 1.8 2.1 2.45 .09
Anxiety 0.9 1.0 1.5 7.58 <.001
Insomnia 0.4 0.6 0.7 4.97 .007
Dementia 0.7 0.5 1.1 11.39 <.001
Pain 15.6 15.8 17.0 1.93 .15
Substance use disorder 0.3 0.3 0.3 0.73 .48
No mental health or pain diagnosis 80.3 80.0 78.1 3.93 .02
Provider type
Family practice 19.6 18.1 20.9 1.70 .14
Internal medicine 21.5 22.1 19.8
Psychiatry 1.1 1.0 1.6
Other medical specialty 57.8 59.0 57.8
aRepresents the weighted percentage of visits by older adults within the time interval.
bIncludes other race and ethnicity
cDiagnosis groups are not mutually exclusive (e.g., a visit of an individual with depression and pain would be represented in both diagnosis rows.
2054 GERLACH ET AL. SEPTEMBER 2017–VOL. 65, NO. 9 JAGS
from its FDA approval in 2009 to augment antidepressants
for depression and growth in off-label use for insomnia,
anxiety, or both. Over the study period, use of TCAs
declined significantly. This decline may be due to greater
recognition by providers of adverse effects associated with
medications with high anticholinergic burden in older
adults,23 with many alternative medications with more-
favorable side effects available for depression, anxiety, and
neuropathy.
This study has several limitations. NAMCS does not
account for whether a prescribed medication is taken regu-
larly versus as needed, so it is possible that the extent of
regular use was overestimated. Because the data were mul-
tiple cross-sectional samples, outcomes associated with
medication use cannot be reported on. Because NAMCS is
a survey of office-based medical practice, it does not
include physicians practicing in other settings or nonphysi-
cian providers. In addition, being based on a survey of
U.S. physicians, the results examine trends only in the U.S.
healthcare system and do not generalize internationally.
Physician nonresponse might have introduced bias into the
results, but the survey weights that NAMCS designed
account for this to produce unbiased national estimates.16
Finally, in 2012, NAMCS began using Census field repre-
sentatives rather than physician office staff to conduct data
collection. NAMCS reports that these changes did not
affect diagnosis results, although the number of medica-
tions reported decreased, for which National Center for
Health Statistics (NCHS) NCHS staff “have researched . . .
[all] possible contributing factors” without clear explana-
tion,16 which suggests that the current study results may
have underestimated the actual increase in CNS polyphar-
macy visits.
In light of the serious health consequences for older
adults associated with CNS polypharmacy, potentially
including falls and death, it is troubling that such prescrib-
ing continues to rise.15 Although this combination of medi-
cations may be appropriate in select populations, use
Table 2. Patterns of Central Nervous System (CNS) Polypharmacy at Visits of Older Adults Seen in Office-Based
Medical Care in the United States: 2011–2013
Medication
Opioid,
n = 465
Benzodiazepine,
n = 393
Selective
Serotonin
Reuptake
Inhibitor,
n = 300
Nonbenzodiazepine
Benzodiazepine
Receptor Agonist
Hypnotic, n = 150
Antipsychotic,
n = 117
Tricyclic
Antidepressant,
n = 87
% (95% Confidence Interval)
Overall, N = 618a 76.2 (70.8–80.9) 61.8 (56.5–66.9) 51.5 (45.7–57.2) 25.6 (20.9–31.0) 18.1 (13.7–23.7) 10.8 (8.2–14.0)
Opioid — 66.0 (58.4–72.8) 62.8 (54.5–70.5) 64.8 (52.8–75.1) 35.9 (24.0–49.8) 61.1 (46.8–73.7)
Benzodiazepine 53.3 (47.3–59.6) — 66.5 (59.1–73.2) 45.3 (34.7–56.5) 67.5 (53.8–78.7) 54.9 (40.8–68.3)
Selective serotonin
reuptake inhibitor
42.4 (36.0–49.2) 55.3 (48.0–62.5) — 47.7 (36.2–59.5) 54.3 (40.2–67.8) 47.4 (34.1–61.0)
Nonbenzodiazepine
benzodiazepine
receptor agonist
hypnotic
21.8 (16.8–27.7) 18.8 (13.8–25.1) 23.8 (17.6–31.3) — 26.3 (15.4–41.2) 18.7 (10.7–30.5)
Antipsychotic 8.5 (5.5–13.1) 19.8 (14.0–27.2) 19.1 (13.0–27.3) 18.6 (10.5–30.9) — 13.9 (7.0–25.7)
Tricyclic
antidepressant
8.6 (6.0–12.2) 9.5 (6.5–13.9) 9.9 (6.5–14.8) 7.8 (4.5–13.4) 8.2 (4.4–14.9) —
aPercentage of CNS polypharmacy overall that includes a given medication class from 2011 to 2013. Within the column for each class, the rows reflect
the proportion of polypharmacy within that specific class that includes the other medication groups. For example, 76.2% of CNS polypharmacy encoun-
ters overall from 2011 to 2013 included an opioid; of those on an opioid, 8.5% were also prescribed an antipsychotic. In contrast, 18.1% of CNS
polypharmacy encounters overall from 2011 to 2013 included an antipsychotic; of those on an antipsychotic, 35.9% were also prescribed an opioid.
Table 3. Trends in Central Nervous System (CNS)
Polypharmacy Constituent Medication Classes at Visits
of Older Adults to Office-Based Physicians in the Uni-
ted States: 204–2013
Medication Group
Percentage of
CNS
Polypharmacy
Visits, N = 1,062
ORa (95%
Confidence
Interval)
P-
Value
2004
–06
2007
–10
2011
–13
Opioid 69.6 67.5 76.2 2.15 (1.19–3.91) .01
Benzodiazepine 68.9 78.7 61.8 0.36 (0.17–0.74) .006
Selective serotonin
reuptake inhibitor
52.5 58.5 51.5 0.63 (0.35–1.15) .13
Nonbenzodiazepine
benzodiazepine
receptor agonist
hypnotic
22.3 26.4 25.6 1.23 (0.67–2.27) .51
Antipsychotic 18.6 22.5 18.1 0.88 (0.48–1.62) .68
Tricyclic
antidepressant
23.9 12.0 10.8 0.31 (0.15–0.66) .002
aThe odds ratio (OR) is associated with a transformed survey year variable
((survey year–2004)/9) and therefore estimates the change in odds of a
visit with the particular medication class of all CNS polypharmacy visits
over the entire 2004–2013 study period. For example, in 2013, the odds
of a Tricyclic antidepressant contributing to CNS polypharmacy were
0.31 relative to 2004. Logistic regression models were adjusted for age,
sex, and race and ethnicity.
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should be considered only after careful assessment of the
risks, benefits, and alternatives. Public attitudes have
grown more favorable toward psychotropic medications,24
and older adults have become more open to mental health
treatment. Although this may lead to better treatment for
some older adults, it may also lead to inappropriate
overtreatment for others. In light of the recent FDA warn-
ing, co-prescribing of opioids and benzodiazepines is par-
ticularly troubling. It is critical to reduce this common and
potentially lethal prescribing. There have been promising
studies implementing structured algorithms to reduce
polypharmacy, including psychotropic medications,
demonstrating success in discontinuing medication without
adverse effects, often with significant improvement in
health outcomes.25 Direct patient education about the
harms potentially associated with medications that con-
tribute to CNS polypharmacy may also lead some people
to initiate discussions about appropriate prescribing, as
demonstrated with chronic benzodiazepine use.26 Lastly,
improving access to evidence-based nonpharmacological
treatments for insomnia, anxiety, or pain might also limit
polypharmacy. In treatment of older adults, the adage
“less is more” holds true, and further work is needed to
emphasize deprescribing in older adults.
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